Transition of Topical Therapy Formulation in Psoriasis Transition of Topical Therapy Formulation in Psoriasis
This study explored dermatologists ' reasons for transitioning psoriasis patients from an ointment or gel formulation to an aerosol foam formulation of calcipotriol and betamethasone dipropionate.Skin Therapy Letter (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 4, 2022 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news
Precursor Immunotherapy to Prevent Squamous Cell Carcinoma
Researchers evaluated whether treatment with calcipotriol plus 5-fluorouracil aided in reducing the risk of squamous cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - April 5, 2019 Category: Cancer & Oncology Authors: Naveed Saleh, MD, MS Source Type: news
Topical Immunotx for Actinic Keratosis May Prevent Cancer
Fewer patients treated with calcipotriol plus 5 - FU developed SCC on treated face, scalp within three years (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 25, 2019 Category: Cancer & Oncology Tags: Dermatology, Oncology, Pharmacy, Journal, Source Type: news
Topical Immunotx for Actinic Keratosis May Prevent Cancer
MONDAY, March 25, 2019 -- A short course of calcipotriol plus 5-fluorouracil (5-FU) treatment for actinic keratosis (AK) is associated with induction of robust T cell immunity and reduced development of squamous cell carcinoma (SCC) within three... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 25, 2019 Category: Pharmaceuticals Source Type: news
The Evolution of Topical Formulations in Psoriasis The Evolution of Topical Formulations in Psoriasis
A new vehicle for delivery of calcipotriol/betamethasone diproprionate, in the form of an aerosol foam, may increase adherence over ointments and gels for mild-to-moderate psoriasis.Skin Therapy Letter (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 23, 2018 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news
Washington University and Harvard Medical School report positive topical immunotherapy trial results
The Washington University School of Medicine in St. Louis and Harvard Medical School have reported positive results from a clinical study of combination of two topical drugs, cream formulation of topical 5-fluorouracil and calcipotriol, to treat earl … (Source: Drug Development Technology)
Source: Drug Development Technology - November 23, 2016 Category: Pharmaceuticals Source Type: news
Topical immunotherapy combo effective against early skin cancer
Researchers from the Washington University School of Medicine and Harvard Medical School have shown that a combination of 2 topical drugs can trigger an immune response against precancerous skin lesions. The study was published yesterday in The Journal of Clinical Investigation.
The 2 drugs, calcipotriol and 5-fluorouracil, have been in use for years – topical 5-fluorouracil is prescribed to treat actinic keratosis. Calcipotriol is indicated by the FDA for psoriasis, an autoimmune disorder that presents with red, scaly patches of skin. The researchers combined the 2 drugs and evaluated the combination’s effic...
Source: Mass Device - November 22, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Drug-Device Combinations Oncology Pharmaceuticals Research & Development Harvard Medical School Washington University Source Type: news
Taclonex (Calcipotriene and Betamethasone Dipropionate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 22, 2016 Category: Drugs & Pharmacology Source Type: news
Taclonex Scalp (Calcipotriene and Betamethasone Dipropionate Topical Suspension) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 6, 2016 Category: Drugs & Pharmacology Source Type: news
LEO Pharma recieves scientific approval of Enstilar® for the treatment of psoriasis in EU
The marketing approval of Enstilar® would make it the first fixed combination topical foam treatment for people living with psoriasis vulgaris in the EU (Source: Pharmacy Europe)
Source: Pharmacy Europe - March 21, 2016 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Legislation & regulation Dermatology Patient care calcipotriol/betamethasone dipropionate enstilar fixed combination topical foam Latest News psoriasis vulgaris Source Type: news
International study shows improved outcomes for psoriasis patients
Interim results from one of the largest and longest clinical trials ever conducted for a topical treatment in psoriasis* showed that after eight weeks of treatment with calcipotriol/betamethasone dipropionate (Daivobet® gel), the treatment was highly efficacious, preferred by patients and improved patients' and the physicians’ assessments of disease severity. (Source: Pharmacy Europe)
Source: Pharmacy Europe - October 29, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Rheumatology Patient care calcipotriol/betamethasone dipropionate Latest News psoriasis Source Type: news
Lipidor announces positive results from Phase I/IIa psoriasis study
Drug delivery company Lipidor, 50% owned by Karolinska Development, has reported positive results from Phase I/IIa psoriasis study of Akvano/calcipotriol spray formulation, a water-free spray formulation containing vitamin D derivative calcipotriol. (Source: Drug Development Technology)
Source: Drug Development Technology - August 27, 2013 Category: Pharmaceuticals Source Type: news
